Dr Lalchandani Labs Ltd (DLCL) is currently trading at 6.19 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Dr Lalchandani Labs Limited is a Delhi/NCR-based diagnostic services company operating NABL-accredited pathology laboratories, multiple collection centres and hospital lab-management contracts, offering routine and specialised tests including biochemistry, histopathology, molecular diagnostics, imaging and corporate health packages under its own brand since its conversion from a partnership in 2017. Financially, the company reported consolidated standalone H1 (ended 30 Sep 2025) total revenue of INR 234.30 lakhs, operating revenue of INR 205.10 lakhs and Profit Before Tax of INR 26.06 lakhs, with Profit After Tax of INR 19.50 lakhs, showing modest profitability despite tightened working capital and a qualified audit report describing accounting gaps and irregular statutory deposits. Balance-sheet highlights show a strong cash balance of INR 351.19 lakhs, but elevated trade receivables of INR 563.28 lakhs and short-term borrowings of INR 458.33 lakhs; notably, the company reports INR 1,015.08 lakhs as ‘money received against share warrants’, a material financing item that demands clarity on dilution, utilisation and investor identity. Operationally the company runs five self-sufficient labs and fifteen collection centres across Delhi/NCR, claims the ability to process c.1,000 samples/hour with same-day reporting, is NABL accredited and empanelled with CGHS, MCD, DJB and other panels, and also provides lab services to several hospitals and charitable retail outlets in the region. The limited review includes qualifications and emphasis points: unpaid instalments to lenders with potential unrecorded penal interest, non-provision for gratuity and leave encashment contrary to AS-15, and irregular deposit of statutory dues (ESI, EPF, TDS), all of which increase contingent liabilities and governance risk despite a qualified conclusion from auditors.

Over the past 52 weeks, Dr Lalchandani Labs Ltd has traded between a low of ₹5.81 and a high of ₹17.99. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Dr Lalchandani Labs Ltd has a market capitalization of approximately 5.70. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Dr Lalchandani Labs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 81.43 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 5.70 Cr, Dr Lalchandani Labs Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Dr Lalchandani Labs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Dr Lalchandani Labs Ltd is 81.43. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.